Proefschrift

Gatenby, R., Zhang, J., and Brown, J. (2019). First strike–second strike strategies in metastatic cancer: lessons from the evolutionary dynamics of extinction. Cancer Research , 79(13):3174–3177. 97 Gause, G. (1934). The Struggle For Existence (1st ed.) . Williams and Wilkins. 76 Gerlee, P. and Altrock, P. (2017). Extinction rates in tumour public goods games. Journal of The Royal Society Interface , 14(134):20170342. 82 Gerlinger, M., Rowan, A., Horswell, S., Larkin, J., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine , 366(10):883–892. 5 Ghaffari, A. and Naserifar, N. (2010). Optimal therapeutic protocols in cancer immunotherapy. Computers in Biology and Medicine , 40(3):261–270. 14, 64 Gillies, R., Flowers, C., Drukteinis, J., and Gatenby, R. (2012). A unifying theory of carcinogenesis, and why targeted therapy doesn’t work. European Journal of Radiology , 81(Supp1):S48–S50. 49 Gillies, R., Kinahan, P., and Hricak, H. (2015). Radiomics: images are more than pictures, they are data. Radiology , 278(2):563–577. 21 Gluzman, M., Scott, J., and Vladimirsky, A. (2020). Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory. Proceedings of the Royal Society B , 287(1925):20192454. 14, 82 Graham, L., Shupe, M., Schneble, E., Flynt, F., et al. (2014). Current approaches and challenges in monitoring treatment responses in breast cancer. Journal of Cancer , 5(1):58– 68. 20 Greaves, M. and Maley, C. (2012). Clonal evolution in cancer. Nature , 481(7381):306–313. 81 Greene, S. and Reid, A. (2003). Moving targets: Fighting resistance in infections, cancers, pests. Microbe Magazine . 23 Grolmusz, V., Chen, J., Emond, R., Cosgrove, P., Pflieger, L., Nath, A., Moos, P., and Bild, A. (2020). Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model. Cancer Cel l International , 20(1):1475–2867. 83 Grossebrummel, H., Peter, T., Mandelkow, R., Weiss, M., Muzzio, D., Zimmermann, U., Walther, R., Jensen, F., Knabbe, C., Zygmunt, M., Burchardt, M., and Stope, M. (2016). Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. International Journal of Oncology , 48(2):793–800. 29 173